2025-12-30 - Analysis Report
Okay, here's a comprehensive analysis of Intuitive Surgical (ISRG) based on the provided data.

**1) Return Rate Comparison**

*   **ISRG Company Overview:** Intuitive Surgical Inc. designs, manufactures, and markets robotic surgical systems.
*   **ISRG Cumulative Return:** 113.53%
*   **S&P 500 (VOO) Cumulative Return:** 103.21%
*   **Divergence:**
    *   Current: 10.7
    *   Relative Divergence: 35.5

**Analysis of Return Rate:** ISRG has outperformed the S&P 500 by a significant margin, evidenced by the 10.7 difference in cumulative returns. The relative divergence of 35.5 indicates that the current divergence isn't near the high end of its historical range, suggesting there's potentially more room for ISRG to outperform.

**Alpha, Beta Analysis Table & Interpretation:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 68.0% | 77.6% | 40.0% | -0.1 | 43.4 |
| 2016-2018  | 64.0% | 72.2% | 49.0% | -0.0 | 57.0 |
| 2017-2019  | 54.0% | 72.2% | 31.0% | 0.2 | 70.3 |
| 2018-2020  | -6.0% | 80.4% | -29.0% | 0.3 | 97.3 |
| 2019-2021  | 29.0% | 80.4% | -18.0% | 0.6 | 128.3 |
| 2020-2022  | -23.0% | 80.4% | -22.0% | 1.2 | 94.7 |
| 2021-2023  | -17.0% | 77.5% | -18.0% | 1.7 | 120.4 |
| 2022-2024  | 36.0% | 77.5% | 15.0% | 1.7 | 186.3 |
| 2023-2025  | 76.0% | 72.7% | 8.0% | 0.8 | 206.3 |

*   **CAGR (Compound Annual Growth Rate):** Shows the average annual growth over the periods.  The CAGR has fluctuated considerably, with strong periods (2015-2019, 2023-2025) and weaker periods (2018-2023).
*   **MDD (Maximum Drawdown):** Indicates the largest peak-to-trough decline during the period. MDD is relatively high, suggesting significant price volatility and potential risk.
*   **Alpha:**  Measures the stock's excess return compared to its benchmark (S&P 500).  Positive alpha indicates outperformance, while negative alpha indicates underperformance. ISRG has experienced both periods of outperformance and underperformance.
*   **Beta:**  Measures the stock's volatility relative to the market. Beta values near 0 suggest minimal market correlation. Beta has increased in recent years, suggesting ISRG has become more market-sensitive.
*   **Cap(B) (Market Capitalization in Billions):** Shows the company's size. The market cap has generally increased over time, indicating growth, but it also shows large fluctuations indicating the impact of external factors such as the COVID-19 Pandemic.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 577.81
*   **Last Market Data:** Price: 575.4, Previous Close: 577.81, Change: -0.42
*   **5-day SMA:** 576.92
*   **20-day SMA:** 565.53
*   **60-day SMA:** 531.8071

**Analysis of Stock Price Fluctuations:** The current price is slightly below the previous close. The short-term moving average (5-day) is above the 20-day and 60-day moving averages, suggesting a recent upward trend. The 20-day SMA being above the 60-day SMA reinforces this trend.

**3) RSI, PPO, and Expected Return**

*   **MRI (Market Risk Indicator):** 0.9 (High Investment Recommended)
*   **RSI (Relative Strength Index):** 51.47
*   **PPO (Percentage Price Oscillator):** 0.0937
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (2 shares - Safe - MRI:0.80)
*   **Recent (20 days) relative divergence change:** 8.0 (+) (Short-term increase)
*   **Expected Return (%):** 23.9%

**Analysis of Indicators:**

*   **MRI:** The high MRI suggests that the overall market conditions are favorable for investment.
*   **RSI:** An RSI of 51.47 is neutral, not indicating overbought or oversold conditions.
*   **PPO:** A positive PPO indicates that the short-term moving average is above the long-term moving average, confirming the upward trend.
*   **Hybrid Signal:** The signal suggests a strong buy, reinforcing the positive outlook.
*   **Divergence Change:** A positive divergence change over the last 20 days indicates recent outperformance relative to the S&P 500.
*   **Expected Return:** The high expected return of 23.9% is very attractive and suggests good long-term growth potential.

**4) Recent News & Significant Events:**

*   **AI Surgical Systems Innovation:** News about innovations in AI surgical systems could positively impact ISRG.
*   **Institutional Holding:** Annex Advisory Services holding a significant position ($27.30 million) indicates confidence in the company.
*   **Valuation Discount:** An article suggesting a 12% discount implies the stock is undervalued.
*   **Share Price Surge:** A recent surge in share price (25% in three months) suggests strong investor interest and positive momentum.
*   **FDA Greenlight:** FDA approval for a new product or procedure is a significant positive catalyst.

**Analysis of News:** The news headlines are overwhelmingly positive, highlighting innovation, undervaluation, institutional support, and regulatory approval.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 2.06)
*   **Target Price (avg/high/low):** 599.60 / 700.00 / 378.00

**Analysis of Analyst Opinions:** The consensus rating of "Buy" and the average target price of 599.60 suggests analysts believe the stock has further upside potential.  The wide range between high and low target prices indicates some uncertainty or varying perspectives on the company's future performance.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출    |
|------------|------|---------|
| 2025-10-22 | 1.98 | 2.51 B$ |
| 2025-07-23 | 1.84 | 2.44 B$ |
| 2025-04-23 | 1.95 | 2.25 B$ |
| 2024-10-18 | 1.59 | 2.04 B$ |
| 2025-10-22 | 1.59 | 2.04 B$ |

**Analysis of Earnings:** Both EPS (Earnings Per Share) and revenue show a general upward trend, indicating positive financial performance. The most recent quarter (2025-10-22) shows the highest EPS and revenue in the provided data.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30 | $2.51B    | 66.36%        |
| 2025-06-30 | $2.44B    | 66.31%        |
| 2025-03-31 | $2.25B    | 64.69%        |
| 2024-12-31 | $2.41B    | 68.04%        |
| 2024-09-30 | $2.04B    | 67.41%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE   |
|--------------|-----------|-------|
| 2025-09-30 | $16.93B   | 4.16% |
| 2025-06-30 | $17.85B   | 3.69% |
| 2025-03-31 | $17.11B   | 4.08% |
| 2024-12-31 | $16.43B   | 4.17% |
| 2024-09-30 | $15.58B   | 3.63% |

**Analysis of Financials:**

*   **Revenue:** Revenue has been steadily increasing, reflecting strong demand for ISRG's products and services.
*   **Profit Margin:** The consistently high-profit margins indicate strong pricing power and efficient operations.
*   **Equity:**  Equity has generally increased, representing the company's growing net worth.
*   **ROE (Return on Equity):** ROE is relatively stable, indicating consistent profitability relative to shareholders' equity.

**7) Comprehensive Analysis (Summary)**

Overall, the data paints a positive picture for Intuitive Surgical (ISRG).

*   **Performance:** ISRG has outperformed the S&P 500, with the potential for further outperformance.
*   **Financial Health:** The company demonstrates strong financial health with increasing revenue, high-profit margins, and a growing equity base.
*   **Growth Potential:** Innovations in AI surgical systems, FDA approvals, and a high expected return suggest significant growth potential.
*   **Market Sentiment:** Positive news headlines, a "Buy" analyst consensus, and institutional investment indicate strong market confidence.
*   **Risks:** The high MDD values suggest potential price volatility. Rising Beta suggests increasing market sensitivity.

**Conclusion:** Based on the available data, ISRG appears to be a promising investment. While risks associated with volatility and market correlation exist, the company's strong financial performance, positive market sentiment, and growth prospects make it an attractive option. The "High Investment Recommended" MRI further supports this conclusion. However, investors should always conduct their own due diligence before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.